Prevention of Bleeding in Total Joint Replacement: Combined Route Administration of Tranexamic Acid
Status:
Completed
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The investigators aimed to compare two doses of intravenous (IV) tranexamic acid (TXA) with a
combined single dose of topical and IV TXA on haemoglobin decline 24 hours after total joint
arthroplasties.
The investigators conducted randomized, double-blind trial. The participants were randomized
to either intrvenous group receiving 2 doses of 1 gram TXA in intravenous route 3 hours
apart, or a combined application group receiving the first 1 gram IV and the topical dose was
1.5 gram after reduction of the fascia.